Progressive Multifocal Leukoencephalopathy

Neurologic Clinics

Volumn 26, Issue 3, 2008, Pages 833-854

  Weber, Thomas ^a  

^a Neurologische Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; BETA INTERFERON; CARMUSTINE; CIDOFOVIR; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOSINE; DACARBAZINE; DACLIZUMAB; ETANERCEPT; FLUDARABINE; GADOLINIUM; GAMMA INTERFERON; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 2; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; OKT 3; RAPAMYCIN; RITUXIMAB; TACROLIMUS; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; DRUG TARGETING; GENE AMPLIFICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INCIDENCE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANDEMIC; PATHOGENESIS; POLYOMA VIRUS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; VIRUS ISOLATION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIGENS, CD4; BRAIN; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DNA; DRUG THERAPY; HEALTH STATUS; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN M; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; PROGNOSIS; RNA, MESSENGER; TOMOGRAPHY, X-RAY COMPUTED;

EID: 47649127788     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2008.03.007     Document Type: Review

References (172)

1. Weber T., and Major E.O. Progressive multifocal leukoencephalopathy: molecular biology, pathogenesis and clinical impact. Intervirology 40 2-3 (1997) 98-111
2. Padgett B.L., Walker D.L., Zu Rhein G.M., et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 297 7712 (1971) 1257-1260
3. Hallervorden J. Eigenartige und nicht rubrizierbare prozesse. In: Bumke O. (Ed). Handbuch der Geisteskrankheiten Die Anatomie der Psychosen (1930), Springer, Berlin 1036-1107
4. Åström K.-E., Mancall E.L., and Richardson E.P. Progressive multifocal leuko-encephalopathy. A hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81 (1958) 93-111
5. Cavanagh J.B., Greenbaum D., Marshall A.H.E., et al. Cerebral demyelination associated with disorders of the reticuloendothelial system. Lancet 274 7102 (1959) 524-529
6. Zu Rhein G., Padgett B.L., Walker D.L., et al. Pituitary function after removal of microadenomas for Cushing's disease. [letter]. N Engl J Med 299 5 (1978) 256-257
7. Frisque R.J., Bream G.L., and Cannella M.T. Human polyomavirus JC virus genome. J Virol 51 2 (1984) 458-469
8. Miller J.R., Barrett R.E., Britton C.B., et al. Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 307 23 (1982) 1436-1438
9. Eng P.M., Turnbull B.R., Cook S.F., et al. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology 67 5 (2006) 884-886
10. San-Andres F.J., Rubio R., Castilla J., et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 36 9 (2003) 1177-1185
11. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 18 (2005) 1912-1925
12. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 4 (2005) 375-381
13. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 4 (2005) 369-374
14. Important drug warning updated safety information. Available at: Genentech biogenidec 2006. Available at: www.rituxan.com/ra/content/Rituxan_DHCPletter Accessed July 1, 2005.
15. Jellinger K.A., Setinek U., Drlicek M., et al. Neuropathology and general autopsy findings in AIDS during the last 15 years. [In Process Citation]. Acta Neuropathol (Berl) 100 2 (2000) 213-220
16. Neuenburg J.K., Brodt H.R., Herndier B.G., et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31 2 (2002) 171-177
17. Venkataramana A., Pardo C.A., McArthur J.C., et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 67 3 (2006) 383-388
18. Hoffmann C., Horst H.A., Albrecht H., et al. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatr 74 8 (2003) 1142-1144
19. Berger J.R., Pall L., Lanska D., et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 4 1 (1998) 59-68
20. Lima M.A., Hanto D.W., Curry M.P., et al. Atypical radiological presentation of progressive multifocal leukoencephalopathy following liver transplantation. J Neurovirol 11 1 (2005) 46-50
21. Whiteman M.L., Post M.J., Berger J.R., et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 187 (1993) 233-240
22. Brooks B.R., and Walker D.L. Progressive multifocal leukoencephalopathy. Neurol Clin 2 2 (1984) 299-313
23. Berenguer J., Miralles P., Arrizabalaga J., et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 36 8 (2003) 1047-1052
24. Roskopf J., Trofe J., Stratta R.J., et al. Pharmacotherapeutic options for the management of human polyomaviruses. Adv Exp Med Biol 577 (2006) 228-254
25. Holman R.C., Janssen R.S., Buehler J.W., et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 41 11 (1991) 1733-1736
26. Skromne E., Rivera V.M., Ontaneda D., et al. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology 66 11 (2006) 1787-1788 author reply -8
27. Royal III W., Dupont B., McGuire D., et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 9 3 (2003) 411-419
28. Marra C.M., Rajicic N., Barker D.E., Cohen B.A., et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16 13 (2002) 1791-1797
29. Marra C.M., Rajicic N., Barker D.E., et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16 13 (2002) 1791-1797
30. Levy R.M., Major E., Ali M.J., et al. Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML). J Neurovirol 7 4 (2001) 382-385
31. Dodge R.T. A case study: the use of cidofovir for the management of progressive multifocal leukoencephalopathy. J Assoc Nurses AIDS Care 10 4 (1999) 70-74
32. Hall C.D., Dafni U., Simpson D., et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338 19 (1998) 1345-1351
33. Steiger M.J., Tarnesby G., Gabe S., et al. Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol 33 4 (1993) 407-411
34. Tashiro K., Doi S., Moriwaka F., et al. Progressive multifocal leucoencephalopathy with magnetic resonance imaging verification and therapeutic trials with interferon. J Neurol 234 6 (1987) 427-429
35. De Luca A., Giancola M.L., Ammassari A., et al. Potent anti-retroviral therapy with or without cidofovir for AIDS- associated progressive multifocal leukoencephalopathy: extended follow- up of an observational study. J Neurovirol 7 4 (2001) 364-368
36. Silva M.T., and Araujo A. Highly active antiretroviral therapy access and neurological complications of human immunodeficiency virus infection: impact versus resources in Brazil. J Neurovirol 11 Suppl 3 (2005) 11-15
37. Antinori A., Cingolani A., Lorenzini P., et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 9 Suppl 1 (2003) 47-53
38. Cinque P., Pierotti C., Vigano M.G., et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 7 4 (2001) 358-363
39. Tassie J.M., Gasnault J., Bentata M., et al. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 13 14 (1999) 1881-1887
40. Gasnault J., Taoufik Y., Goujard C., et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 5 4 (1999) 421-429
41. Dworkin M.S., Wan P.C., Hanson D.L., et al. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 180 3 (1999) 621-625
42. Clifford D.B., Yiannoutsos C., Glicksman M., et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52 3 (1999) 623-625
43. Huang S.S., Skolasky R.L., Dal Pan G.J., et al. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol 4 3 (1998) 324-332
44. Berger J.R., Levy R.M., Flomenhoft D., et al. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44 3 (1998) 341-349
45. De Luca A., Giancola M.L., Ammassari A., et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182 4 (2000) 1077-1083
46. Elliot B., Aromin I., Gold R., et al. 2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet 349 (1997) 850
47. Sacktor N., Lyles R.H., Skolasky R., et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 56 2 (2001) 257-260
48. Garcia-Suarez J., de Miguel D., Krsnik I., et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 80 4 (2005) 271-281
49. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 9 (2006) 924-933
50. Hamilton R.S., Gravell M., and Major E.O. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 38 1 (2000) 105-109
51. Weber T., Beck R., Stark E., et al. Comparative analysis of intrathecal antibody synthesis and DNA amplification for the diagnosis of cytomegalovirus infection of the central nervous system in AIDS patients. J Neurol 241 7 (1994) 407-414
52. Agostini H.T., Yanagihara R., Davis V., et al. Asian genotypes of JC virus in Native Americans and in a Pacific Island population: markers of viral evolution and human migration. Proc Natl Acad Sci U S A 94 26 (1997) 14542-14546
53. Shackelton L.A., Rambaut A., Pybus O.G., et al. JC virus evolution and its association with human populations. J Virol 80 20 (2006) 9928-9933
54. Berger J.R., and Concha M. Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. J Nephrol 1 1 (1995) 5-18
55. Fong I.W., and Toma E. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group. Clin Infect Dis 20 5 (1995) 1305-1310
56. Gillespie S.M., Chang Y., Lemp G., et al. Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981-1989. Ann Neurol 30 4 (1991) 597-604
57. von Einsiedel R.W., Fife T.D., Aksamit A.J., et al. Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature. J Neurol 240 (1993) 391-406
58. Weber T., Turner R.W., Frye S., et al. Progressive multifocal leukoencephalopathy diagnosed by amplification of JC virus-specific DNA from cerebrospinal fluid. AIDS 8 (1994) 49-57
59. Thurnher M.M., Thurnher S.A., Muhlbauer B., et al. Progressive multifocal leukoencephalopathy in AIDS: initial and follow-up CT and MRI. Neuroradiology 39 9 (1997) 611-618
60. Chang L., Ernst T., Tornatore C., et al. Metabolite abnormalities in progressive multifocal lenkoencephalopathy by proton magnetic resonance spectroscopy. Neurology 48 (1997) 836-845
61. Post M.J., Yiannoutsos C., Simpson D., et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 20 10 (1999) 1896-1906
62. Iranzo A., Moreno A., Pujol J., et al. Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS. J Neurol Neurosurg Psychiatr 66 4 (1999) 520-523
63. Simone I.L., Federico F., Tortorella C., et al. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatr 64 4 (1998) 516-523
64. Huang D., Cossoy M., Li M., et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 62 1 (2007) 34-39
65. Stuve O., Marra C.M., Bar-Or A., et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63 10 (2006) 1383-1387
66. Niino M., Bodner C., Simard M.L., et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59 5 (2006) 748-754
67. Dubois V., Moret H., Lafon M.E., et al. Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study. J Neurovirol 5 5 (1998) 539-544
68. Weber T. Laboratory findings in progressive multifocal leukoencephalopathy. In: Kahalili K., and Stoner G.L. (Eds). Human polyomaviruses molecular and clinical perspectives (2001), Wiley-Lis, New York 337-358
69. Langer-Gould A., and Steinman L. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr Neurol Neurosci Rep 6 3 (2006) 253-258
70. Moret H., Brodard V., Barranger C., et al. New commercially available PCR and microplate hybridization assay for detection and differentiation of human polyomaviruses JC and BK in cerebrospinal fluid, serum, and urine samples. J Clin Microbiol 44 4 (2006) 1305-1309
71. Koralnik I.J., Boden D., Mai V.X., et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52 2 (1999) 253-260
72. Antinori A., Ammassari A., De Luca A., et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 48 3 (1997) 687-694
73. Weber T., Turner R.W., Frye S., et al. Specific diagnosis of progressive multifocal leukoencephalopathy by polymerase chain reaction. J Infect Dis 169 (1994) 1138-1141
74. Cinque P., Brytting M., Vago L., et al. Epstein-Barr virus DNA in cerebrospinal fluid from patients with AlDS-related primary Iymphoma of the central nervous system. Lancet 342 8868 (1993) 398-401
75. Weber T., Trebst C., Frye S., et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 176 1 (1997) 250-254
76. Weber T. Cerebrospinal fluid analysis for the diagnosis of human immunodeficiency virus-related neurologic diseases. Semin Neurol 19 2 (1999) 223-233
77. Bossolasco S., Calori G., Moretti F., et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 40 5 (2005) 738-744
78. Marzocchetti A., Di Giambenedetto S., Cingolani A., et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 43 8 (2005) 4175-4177
79. Guillaume B., Sindic C.J., and Weber T. Progressive multifocal leukoencephalopathy: simultaneous detection of JCV DNA and anti-JCV antibodies in the cerebrospinal fluid. Eur J Neurol 7 1 (2000) 101-106
80. Giudici B., Vaz B., Bossolasco S., et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30 1 (2000) 95-99
81. Goldmann C., Petry H., Frye S., et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 73 5 (1999) 4465-4469
82. Goldmann C., Stolte N., Nisslein T., et al. Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J Virol Methods 90 1 (2000) 85-90
83. Darbinyan A., Darbinian N., Safak M., et al. Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene 21 36 (2002) 5574-5581
84. Safak M., Barrucco R., Darbinyan A., et al. Interaction of JC virus agno protein with T antigen modulates transcription and replication of the viral genome in glial cells. J Virol 75 3 (2001) 1476-1486
85. Kaniowska D., Kaminski R., Amini S., et al. Cross-interaction between JC virus agnoprotein and human immunodeficiency virus type 1 (HIV-1) Tat modulates transcription of the HIV-1 long terminal repeat in glial cells. J Virol 80 18 (2006) 9288-9299
86. Okada Y., Endo S., Takahashi H., et al. Distribution and function of JCV agnoprotein. J Neurovirol 7 4 (2001) 302-306
87. Bollag B., Chuke W.F., and Frisque R.J. Hybrid genomes of the polyomaviruses JC virus, BK virus, and simian virus 40: identification of sequences important for efficient transformation. J Virol 63 2 (1989) 863-872
88. Dörries K. New aspects in the pathogenesis of polyomavirus-induced disease. Adv Virus Res 48 (1997) 205-261
89. Khalili K. Human neurotropic JC virus and its association with brain tumors. Dis Markers 17 3 (2001) 143-147
90. White M.K., Gordon J., Reiss K., et al. Human polyomaviruses and brain tumors. Brain Res Brain Res Rev 50 1 (2005) 69-85
91. Bollag B., Kilpatrick L.H., Tyagarajan S.K., et al. JC virus T'135, T'136 and T'165 proteins interact with cellular p107 and p130 in vivo and influence viral transformation potential. J Neurovirol 12 6 (2006) 428-442
92. Frisque R.J. Structure and function of JC virus T' proteins. J Neurovirol 7 4 (2001) 293-297
93. Henson J.W., Schnitker B.L., Lee T.S., et al. Cell-specific activation of the glial-specific JC virus early promoter by large T antigen. J Biol Chem 270 22 (1995) 13240-13245
94. Bollag B., Prins C., Snyder E.L., et al. Purified JC virus T and T' proteins differentially interact with the retinoblastoma family of tumor suppressor proteins. Virology 274 1 (2000) 165-178
95. Staib C., Pesch J., Gerwig R., et al. p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T-antigen. Virology 219 1 (1996) 237-246
96. Raj G.V., and Khalili K. Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Virology 213 2 (1995) 283-291
97. Sadowska B., Barrucco R., Khalili K., et al. Regulation of human polyomavirus JC virus gene transcription by AP-1 in glial cells. J Virol 77 1 (2003) 665-672
98. Safak M., and Khalili K. Physical and functional interaction between viral and cellular proteins modulate JCV gene transcription. J Neurovirol 7 4 (2001) 288-292
99. Devireddy L.R., Kumar K.U., Pater M.M., et al. BAG-1, a novel Bcl-2-interacting protein, activates expression of human JC virus. J Gen Virol 81 Pt 2 (2000) 351-357
100. Monaco M.C., Sabath B.F., Durham L.C., et al. JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. PG-9687-95. J Virol 75 20 (2001)
101. Sumner C., Shinohara T., Durham L., et al. Expression of multiple classes of the Nuclear Factor-1 family in the developing human brain: differential expression of two classes of NF-1 genes. J Neurovirol 2 (1996) 87-100
102. Messam C.A., Hou J., Gronostajski R.M., et al. Lineage pathway of human brain progenitor cells identified by JC virus susceptibility. Ann Neurol 53 5 (2003) 636-646
103. Ravichandran V., Sabath B.F., Jensen P.N., et al. Interactions between c-Jun, Nuclear Factor-1 and JC virus promoter sequences: implications for viral tropism. J Virol 80 21 (2006) 10506-10513
104. Ohsumi S., Motoi M., and Ogawa K. Induction of undifferentiated tumors by JC virus in the cerebrum of rats. Acta Pathol Jpn 36 6 (1986) 815-825
105. Major E.O., Mourrain P., and Cummins C. JC virus-induced owl monkey glioblastoma cells in culture: biological properties associated with the viral early gene product. Virology 136 2 (1984) 359-367
106. Krynska B., Otte J., Franks R., et al. Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals. Oncogene 18 1 (1999) 39-46
107. Ricciardiello L., Chang D.K., Laghi L., et al. Mad-1 is the exclusive JC virus strain present in the human colon, and its transcriptional control region has a deleted 98-base-pair sequence in colon cancer tissues. J Virol 75 4 (2001) 1996-2001
108. Monaco M.C.G., Jensen P.N., Hou J., et al. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. [in Process Citation]. J Virol 72 12 (1998) 9918-9923
109. Croul S., Otte J., and Khalili K. Brain tumors and polyomaviruses. J Neurovirol 9 2 (2003) 173-182
110. Newcomb P.A., Bush A.C., Stoner G.L., et al. No evidence of an association of JC virus and colon neoplasia. Cancer Epidemiol Biomarkers Prev 13 4 (2004) 662-666
111. Gillison M.L., Chen R., Goshu E., et al. Human retinoblastoma is not caused by known pRb-inactivating human DNA tumor viruses. Int J Cancer 120 7 (2007) 1482-1490
112. Rollison D.E., Helzlsouer K.J., Alberg A.J., et al. Serum antibodies to JC virus, BK virus, simian virus 40, and the risk of incident adult astrocytic brain tumors. Cancer Epidemiol Biomarkers Prev 12 5 (2003) 460-463
113. Rollison D.E., Engels E.A., Halsey N.A., et al. Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 15 3 (2006) 543-550
114. Power C., Gladden J.G., Halliday W., et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54 3 (2000) 743-746
115. Liu C.K., Wei G., and Atwood W.J. Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids. J Virol 72 6 (1998) 4643-4649
116. Komagome R., Sawa H., Suzuki T., et al. Oligosaccharides as receptors for JC virus. J Virol 76 24 (2002) 12992-13000
117. Eash S., Tavares R., Stopa E.G., et al. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. Am J Pathol 164 2 (2004) 419-428
118. Sabath B.F., and Major E.O. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 186 Suppl 2 (2002) S180-S186
119. Pho M.T., Ashok A., and Atwood W.J. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 74 5 (2000) 2288-2292
120. Elphick G.F., Querbes W., Jordan J.A., et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306 5700 (2004) 1380-1383
121. Bhatnagar A., Sheffler D.J., Kroeze W.K., et al. Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J Biol Chem 279 33 (2004) 34614-34623
122. Zheng H.Y., Kitamura T., Takasaka T., et al. Unambiguous identification of JC polyomavirus strains transmitted from parents to children. Arch Virol 149 2 (2004) 261-273
123. Hogan T.F., Borden E.C., McBain J.A., et al. Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med 92 3 (1980) 373-378
124. Kitamura T., Aso Y., Kuniyoshi N., et al. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis 161 6 (1990) 1128-1133
125. Chang H., Wang M., Tsai R.T., et al. High incidence of JC viruria in JC-seropositive older individuals. J Neurovirol 8 5 (2002) 447-451
126. Houff S.A., Major E.O., Katz D.A., et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318 5 (1988) 301-305
127. Knowles W.A., and Sasnauskas K. Comparison of cell culture-grown JC virus (primary human fetal glial cells and the JCI cell line) and recombinant JCV VP1 as antigen for the detection of anti-JCV antibody by haemagglutination inhibition. J Virol Methods 109 1 (2003) 47-54
128. Knowles W.A., Gibson P.E., Hand J.F., et al. An M-antibody capture radioimmunoassay (MACRIA) for detection of JC virus-specific IgM. J Virol Methods 40 1 (1992) 95-105
129. Knowles W.A., Luxton R.W., Hand J.F., et al. The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leucoencephalopathy. Clin Diagn Virol 4 (1995) 183-194
130. Sindic C.J., Trebst C., Van Antwerpen M.P., et al. Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. J Neuroimmunol 76 1-2 (1997) 100-104
131. Richardson E.P.J. Progressive multifocal leukoencephalopathy. N Engl J Med 265 (1961) 815-823
132. Ellison G.W. Progressive multifocal leukoencephalopathy (PML). I. Investigation of the immunologic status of a patient with lymphosarcoma and PML. J Neuropathol Exp Neurol 28 3 (1969) 501-506
133. Knight A., O'Brien P., and Osoba D. "Spontaneous" progressive multifocal leukoencephalopathy. Immunologic aspects. Ann Intern Med 77 2 (1972) 229-233
134. Willoughby E., Price R.W., Padgett B.L., et al. Progressive multifocal leukoencephalopathy (PML): in vitro cell-mediated immune responses to mitogens and JC virus. Neurology 30 3 (1980) 256-262
135. Frye S., Trebst C., Dittmer U., et al. Efficient production of JC virus in SVG cells and the use of purified viral antigens for analysis of specific humoral and cellular immune response. J Virol Methods 63 1-2 (1997) 81-92
136. Weber T., Weber F., Petry H., et al. Immune response in progressive multifocal leukoencephalopathy: An overview. J Neurovirol 7 4 (2001) 311-317
137. Koralnik I.J. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol 8 Suppl 2 (2002) 59-65
138. Lima M.A., Marzocchetti A., Autissier P., et al. Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 81 7 (2007) 3361-3368
139. Koralnik I.J., Du Pasquier R.A., Kuroda M.J., et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope.PG - 499-504. J Immunol 168 1 (2002) 499-504
140. Du Pasquier R.A., Schmitz J.E., Jean-Jacques J., et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 78 18 (2004) 10206-10210
141. Du Pasquier R.A., Kuroda M.J., Zheng Y., et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127 (2004) 1970-1978
142. Bauer W.R., Turel A.P.J., and Johnson K.P. Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. JAMA 226 2 (1973) 174-176
143. Berger J.R., Pall L., McArthur J., et al. A pilot study of recombinant alpha 2a interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy. Neurology 42 Suppl 3 (1992) 257
144. Weck P.K., Buddin D.A., and Whisnant J.K. Interferons in the treatment of genital human papillomavirus infections. Am J Med 85 2A (1988) 159-164
145. Geschwind M., Skolasky R., Royal W., et al. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 7 4 (2001) 353-357
146. Heide W., Kömpf D., Reusche E., et al. Failure of cytarabine/interferon therapy in progressive multifocal leukoencephalopathy. Ann Neurol 37 3 (1995) 412-413
147. Re D., Bamborschke S., Feiden W., et al. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 23 3 (1999) 295-298
148. Jaeckle K.A., Przepiorka D., Birdwell R.R., et al. Favorable response of progressive multifocal leukoencephalopathy (PML) to treatment with interleukin-2. Neurology 48 Suppl 2 (1997) A26
149. Kunschner L., and Scott T.F. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 65 9 (2005) 1510
150. Andrei G., Snoeck R., Vandeputte M., et al. Activities of various compounds against murine and primate polyomaviruses. Antimicrobial Agents Chemother 41 3 (1997) 587-593
151. Blick G., Whiteside M., Griegor P., et al. Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin Infect Dis 26 1 (1998) 191-192
152. Garvey L., Thomson E.C., and Taylor G.P. Progressive multifocal leukoencephalopathy: prolonged survival in patients treated with protease inhibitors and cidofovir: a case series. AIDS 20 5 (2006) 791-793
153. de Luca A., Fantoni M., Tartaglione T., et al. Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 52 4 (1999) 891-892
154. Wyen C., Hoffmann C., Schmeisser N., et al. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 37 2 (2004) 1263-1268
155. Gasnault J., Kousignian P., Kahraman M., et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 7 4 (2001) 375-381
156. Viallard J.F., Lazaro E., Lafon M.E., et al. Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 46 11 (2005) 1659-1662
157. Houston S., Roberts N., and Mashinter L. Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus. Clin Infect Dis 32 1 (2001) 150-152
158. Salmaggi A., Maccagnano E., Castagna A., et al. Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. Neurol Sci 22 1 (2001) 17-20
159. Osorio S., De La Camara R., Golbano N., et al. Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant 30 12 (2002) 963-966
160. Herrlinger U., Schwarzler F., Beck R., et al. Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease. J Neurol 250 5 (2003) 612-614
161. Terrier B., Martinez V., Seilhean D., et al. Progressive multifocal leukoencephalopathy mimicking cerebral vasculitis in systemic granulomatosis. J Infect 54 3 (2007) e133-e135
162. Kerr D.A., Chang C.F., Gordon J., et al. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 196 2 (1993) 612-618
163. Vollmer-Haase J., Young P., and Ringelstein E.B. Efficacy of camptothecin in progressive multifocal leukoencephalopathy. Lancet 349 (1997) 1366
164. Yiannoutsos C.T., Major E.O., Curfman B., et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 45 6 (1999) 816-821
165. Taoufik Y., Gasnault J., Karaterki A., et al. Prognostic value of JC Virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 178 6 (1998) 1816-1820
166. Garcia De Viedma D., Diaz Infantes M., Miralles P., et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin Infect Dis 34 12 (2002) 1568-1575
167. Safdar A., Rubocki R.J., Horvath J.A., et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 35 10 (2002) 1250-1257
168. Martinez J.V., Mazziotti J.V., Efron E.D., et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 67 9 (2006) 1692-1694
169. Miralles P., Berenguer J., Lacruz C., et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 15 14 (2001) 1900-1902
170. Berger J.R., Gallo B., and Concha M. Progressive miultifocal leukoencephalopathy. In: Berger J.R., and Levy R.M. (Eds). AIDS and the nervous system (1997), Lippincott-Raven, Philadelphia 569-594
171. Fong I.W., Britton C.B., Luinstra K.E., et al. Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Clin Microbiol 33 2 (1995) 484-486
172. Matthews B. Symptoms and signs of multiple sclerosis. In: Compston A., Ebers G., and Lassmann H. (Eds). McAlpine's multiple sclerosis (1998), Chruchill Livingstone, London 145-190